184 related articles for article (PubMed ID: 26025018)
21. Exploration of heterogeneity in distributed research network drug safety analyses.
Hansen RA; Zeng P; Ryan P; Gao J; Sonawane K; Teeter B; Westrich K; Dubois RW
Res Synth Methods; 2014 Dec; 5(4):352-70. PubMed ID: 26052957
[TBL] [Abstract][Full Text] [Related]
22. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
[TBL] [Abstract][Full Text] [Related]
23. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'.
Gagne JJ; Schneeweiss S
Stat Med; 2013 Mar; 32(6):1073-4. PubMed ID: 23413214
[No Abstract] [Full Text] [Related]
24. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.
Lin KJ; Schneeweiss S
Clin Pharmacol Ther; 2016 Aug; 100(2):147-59. PubMed ID: 26916672
[TBL] [Abstract][Full Text] [Related]
25. Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting.
Nelson JC; Ulloa-Pérez E; Bobb JF; Maro JC
J Clin Epidemiol; 2019 Aug; 112():77-86. PubMed ID: 31108199
[TBL] [Abstract][Full Text] [Related]
26. Quantitative methods in pharmacovigilance: focus on signal detection.
Hauben M; Zhou X
Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
[TBL] [Abstract][Full Text] [Related]
27. Outliers and patients with adverse drug reactions.
Edwards IR
Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
[No Abstract] [Full Text] [Related]
28. The class imbalance problem detecting adverse drug reactions in electronic health records.
Santiso S; Casillas A; Pérez A
Health Informatics J; 2019 Dec; 25(4):1768-1778. PubMed ID: 30230408
[TBL] [Abstract][Full Text] [Related]
29. Drug-safety pilot makes the grade.
Ledford H
Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
[No Abstract] [Full Text] [Related]
30. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
Ball R
Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
[TBL] [Abstract][Full Text] [Related]
31. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
Hauben M; Reich L; Chung S
Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
[TBL] [Abstract][Full Text] [Related]
32. Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning.
Ransohoff JD; Nikfarjam A; Jones E; Loew B; Kwong BY; Sarin KY; Shah NH
JAMA Oncol; 2018 Apr; 4(4):581-583. PubMed ID: 29494731
[TBL] [Abstract][Full Text] [Related]
33. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
34. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
35. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
36. [Benefits of large healthcare databases for drug risk research].
Garbe E; Pigeot I
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Aug; 58(8):829-837. PubMed ID: 26092163
[TBL] [Abstract][Full Text] [Related]
37. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'.
Ryan PB; Madigan D; Stang PE; Marc Overhage J; Racoosin JA; Hartzema AG
Stat Med; 2013 Mar; 32(6):1075-7. PubMed ID: 23413215
[No Abstract] [Full Text] [Related]
38. [Analysis of Spontaneously Reported Adverse Events].
Nakamura M
Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the completeness and accuracy of MedWatch data.
Getz KA; Stergiopoulos S; Kaitin KI
Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
[TBL] [Abstract][Full Text] [Related]
40. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
Ryan PB; Madigan D; Stang PE; Overhage JM; Racoosin JA; Hartzema AG
Stat Med; 2012 Dec; 31(30):4401-15. PubMed ID: 23015364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
